若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

RosetteSep™人骨髓祖细胞预富集抗体混合物

免疫密度负选试剂混合物

产品号 #(选择产品)

产品号 #15027_C

免疫密度负选试剂混合物

产品优势

  • 快捷、操作简单
  • 不需要特殊设备或额外培训
  • 获得的活细胞无标记

产品组分包括

  • RosetteSep™人骨髓祖细胞预富集抗体混合物(产品号#15027)
    • RosetteSep™人骨髓祖细胞预富集抗体混合物,2mL
  • RosetteSep™人骨髓祖细胞预富集抗体混合物(产品号#15067)
    • RosetteSep™人骨髓祖细胞预富集抗体混合物,5x2mL
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品

总览

RosetteSep™人骨髓祖细胞预富集抗体混合物 通过负选从全骨髓去除谱系特异性细胞来 预富集祖细胞。四聚体抗体复合物可识别CD3,、CD11b 、 CD14 、 CD16 、 CD19 、 CD56 、 CD66b以及红细胞(RBC)上的糖蛋白A,从而靶向去除非目的细胞。使用密度梯度离心液如Lymphoprep™(产品号 #18060)离心后 ,非目的细胞会与红细胞一起沉淀。预富集的祖细胞为血浆和密度梯度离心液的交界界面中高度富集的细胞。

磁体兼容性
 
 
亚型
细胞分选试剂盒
 
细胞类型
造血干/祖细胞
 
种属

 
样本来源
Bone Marrow
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
RosetteSep
 
研究领域
免疫,干细胞生物学
 

实验数据

FACS Profile Results With RosetteSep™ Human Bone Marrow Progenitor CellPre-Enrichment Kit

Figure 1. FACS Profile Results With RosetteSep™ Human Bone Marrow Progenitor Cell Pre-Enrichment Kit

Results (mean ± 1 S.D.): Enrichment of CD34+ Cells: 25 ± 10%. Fold Enrichment of CFC: 10-53 Fold

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
15067, 15027
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
15067, 15027
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (4)

常见问题

What is RosetteSep™?

RosetteSep™ is a rapid cell separation procedure for the isolation of purified cells directly from whole blood, without columns or magnets.

How does RosetteSep™ work?

The antibody cocktail crosslinks unwanted cells to red blood cells (RBCs), forming rosettes. The unwanted cells then pellet with the free RBCs when centrifuged over a density centrifugation medium (e.g. Ficoll-Paque™ PLUS, Lymphoprep™).

What factors affect cell recovery?

The temperature of the reagents can affect cell recovery. All reagents should be at room temperature (sample, density centrifugation medium, PBS, centrifuge) before performing the isolations. Layering can also affect recovery so be sure to carefully layer the sample to avoid mixing with the density centrifugation medium as much as possible. Be sure to collect the entire enriched culture without disturbing the RBC pellet. A small amount of density centrifugation medium can be collected without worry.

Which cell samples can RosetteSep™ be used with?

RosetteSep™ can be used with leukapheresis samples, bone marrow or buffy coat, as long as: the concentration of cells does not exceed 5 x 107 per mL (can dilute if necessary); and there are at least 100 RBCs for every nucleated cell (RBCs can be added if necessary).

Can RosetteSep™ be used with previously frozen or cultured cells?

Yes. Cells should be re-suspended at 2 - 5 x 107 cells / mL in PBS + 2% FBS. Fresh whole blood should be added at 250 µL per mL of sample, as a source of red cells.

Can RosetteSep™ be used to enrich progenitors from cord blood?

Yes. Sometimes cord blood contains immature nucleated red cells that have a lower density than mature RBCs. These immature red cells do not pellet over Ficoll™, which can lead to a higher RBC contamination than peripheral blood separations.

Does RosetteSep™ work with mouse cells?

No, but we have developed EasySep™, a magnetic-based cell isolation system which works with mouse and other non-human species.

Which anticoagulant should be used with RosetteSep™?

Peripheral blood should be collected in heparinized Vacutainers. Cord blood should be collected in ACD.

Should the anticoagulant be washed off before using RosetteSep™?

No, the antibody cocktail can be added directly to the sample.

文献 (2)

Growth of mesenchymal stem cells on electrospun type I collagen nanofibers. Shih Y-RV et al. Stem cells (Dayton, Ohio) 2006 NOV

Abstract

We reconstituted type I collagen nanofibers prepared by electrospin technology and examined the morphology, growth, adhesion, cell motility, and osteogenic differentiation of human bone marrow-derived mesenchymal stem cells (MSCs) on three nano-sized diameters (50-200, 200-500, and 500-1,000 nm). Results from scanning electron microscopy showed that cells on the nanofibers had a more polygonal and flattened cell morphology. MTS (3-[4,5-dimethythiazol-2-yl]-5-[3-carboxy-methoxyphenyl]-2-[4-sul-fophenyl]-2H-tetrazolium compound) assay demonstrated that the MSCs grown on 500-1,000-nm nanofibers had significantly higher cell viability than the tissue culture polystyrene control. A decreased amount of focal adhesion formation was apparent in which quantifiable staining area of the cytoplasmic protein vinculin for the 200-500-nm nanofibers was 39% less compared with control, whereas the area of quantifiable vinculin staining was 45% less for both the 200-500-nm and 500-1,000-nm nanofibers. The distances of cell migration were quantified on green fluorescent protein-nucleofected cells and was 56.7%, 37.3%, and 46.3% for 50-200, 200-500, and 500-1,000 nm, respectively, compared with those on the control. Alkaline phosphatase activity demonstrated no differences after 12 days of osteogenic differentiation, and reverse transcription-polymerase chain reaction (RT-PCR) analysis showed comparable osteogenic gene expression of osteocalcin, osteonectin, and ostepontin between cells differentiated on polystyrene and nanofiber surfaces. Moreover, single-cell RT-PCR of type I collagen gene expression demonstrated higher expression on cells seeded on the nanofibers. Therefore, type I collagen nanofibers support the growth of MSCs without compromising their osteogenic differentiation capability and can be used as a scaffold for bone tissue engineering to facilitate intramembranous bone formation. Further efforts are necessary to enhance their biomimetic properties.
Susceptibility of human fetal mesenchymal stem cells to Kaposi sarcoma-associated herpesvirus. Parsons CH et al. Blood 2004 NOV

Abstract

Recent reports link Kaposi sarcoma-associated herpesvirus (KSHV) infection of bone marrow cells to bone marrow failure and lymphoproliferative syndromes. The identity of the infected marrow cells, however, remains unclear. Other work has demonstrated that circulating mononuclear cells can harbor KSHV where its detection predicts the onset and severity of Kaposi sarcoma. In either setting, bone marrow precursors may serve as viral reservoirs. Since mesenchymal stem cells (MSCs) in human bone marrow regulate the differentiation and proliferation of adjacent hematopoietic precursors, we investigated their potential role in KSHV infection. Our results indicate that primary MSCs are susceptible to both cell-free and cell-associated KSHV in culture. Moreover, infection persisted within nearly half of the cells for up to 6 weeks. Thus, MSCs possess a clear capacity to support KSHV infection and warrant further exploration into their potential role in KSHV-related human disease.

更多信息

更多信息
种属 Human
Magnet Compatibility  
样本来源 Bone Marrow
Selection Method Negative
标记抗体
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.